Introduction
============

Much of what we know and teach about the epidemiology of musculoskeletal sarcomas derives from retrospective series collected at large teaching hospitals. Many of these series have been reported in peer-reviewed literature and have been included in published textbooks [@b1]. The single largest report of which we are aware included 26,758 soft tissue sarcomas [@b2], however, this series did not report the survivorship of patients diagnosed with these sarcomas.

Because of the relative infrequency of musculoskeletal sarcomas, few institutions will gather sufficient numbers to provide thorough epidemiologic and descriptive data. Further advances regarding soft tissue sarcoma epidemiology, especially rare types of soft tissue sarcomas, will come from concerted efforts to collect data within tumor registries. The two largest tumor registries in the United States are the National Cancer Data Base (NCDB) of the American College of Surgeons (ACOS) and the National Cancer Institute\'s Surveillance, Epidemiology and End Results (SEER) program.

The NCDB is a joint project of the American Cancer Society and the Commission on Cancer of the ACOS. The ACOS has executed a Business Associate Agreement that includes a data-use agreement with each of its Commission on Cancer-accredited hospitals. The NCDB, established in 1989, is a nationwide, facility based, comprehensive clinical surveillance resource oncology data set that currently captures ∼70% of all newly diagnosed malignancies in the US annually <http://www.facs.org/cancer/ncdb/index.html>.

We wanted to determine from the NCDB the demographic and survivorship information for patients with 34 soft tissue sarcomas. We specifically wanted to report these data for these histologic subtypes of sarcomas as adequate numbers of patients with many of these infrequently encountered sarcomas do not exist within single institution-based series. For instance, controversy exists within the literature as to whether biphasic synovial sarcoma has better, worse, or similar prognosis to Nonbiphasic Synovial Sarcoma [@b3]--[@b6]. Only through analysis of an extensive database of cases from a less-biased source can such an accurate assessment of the potential prognostic differences be performed.

We hypothesized that these data would confirm previously established demographic characteristics of patients with these soft tissue sarcomas but that in the least common sarcomas, demographic distribution may differ from prior reports. We also hypothesized that the data would represent more accurate prognostic data as there would likely be less selection bias than that present in individual center-based reports. We believe, as others have suggested <http://skepdic.com/posoutbias.html>, that researchers and centers tend to favor reporting good results, and since surgical series typically only include reported cases subjected to attempted surgical cures, we hypothesized that the survivorship rates would be lower than rates frequently reported in individual institution-based series.

Methods
=======

The NCDB currently collects data for all cancer patients diagnosed or given first course treatment at facilities accredited by the Commission on Cancer. Each year, there are ∼1500 Commission on Cancer-accredited cancer centers in the United States. This number varies slightly from year to year. (<http://www.facs.org/cancer/ncdb/index.html>) The NCDB has never reported the collected data on soft tissue sarcomas, despite the extensive accumulation of demographic and survivorship data on such sarcomas.

Before 1997, submission of cancer patient records to the NCDB was voluntary and was open to all cancer facilities in the Unites States. Beginning in 1997, data collection was mandated as a requirement of CoC-accredited program, allowing nonaccredited programs to continue to voluntarily report cases to the NCDB. In 2000, data collection was further limited to only CoC- accredited programs. Data quality checks against all cases were conducted at the local level as well as the NCDB on receipt of data submissions. Nationally standardized cancer registry edit reports are generated by the NCDB and returned to participating hospitals for review, correction, and resubmission when data errors or data conflicts were found.

The senior author applied for research access to the NCDB data on bone and soft tissue sarcomas through the NCDB- beta Participant User File (*β*PUF) research program, for the purpose of studying and reporting the available data on musculoskeletal sarcomas.

From 1998 to 2010, 87,087 soft tissue sarcomas were reported from 1588 hospitals to the NCDB, a mean number of 54.8 cases per facility over a 13-year period. We selected 34 of the 239 soft tissue sarcomas reported to the NCDB that are commonly encountered by orthopedic oncologists. We selected only those histologic entities that included a minimum of 50 distinct cases.

These 34 soft tissue sarcomas were extracted from the NCDB using the appropriate second and third editions of the WHO International Classification of Disease for Oncology (ICD-0-2/3) site (C40.0-C40.9, C41.0-C41.9) and histology codes. Data were abstracted using coding guidelines documented in the Registry Operations and Data Standards manual for cases diagnosed before 2003 and the Facility Oncology Registry Data Standards manual for diagnosis year 2003 and beyond.

The 1998--2010 annual reports to the NCDB included 63,714 cases of soft tissue sarcomas with the 34 histologies listed in the data tables. The most common soft tissue sarcoma in our report is malignant fibrous histiocytoma (MFH), which includes 12,754 cases over a 13-year period. MFH is followed by Sarcoma NOS (not otherwise specified) and Myxoid Liposarcoma, which occurred at frequencies of 7842 cases and 3996 cases, respectively.

Data analyzed include patient gender, age (Note: the *β*PUF program only shared data on patients of at least 18 years of age), race, date of initial diagnosis by year, anatomic site of primary tumor, tumor grade (well differentiated, moderately differentiated, poorly differentiated, undifferentiated), tumor size, and 2-year and 5-year survivorship. Anatomic site coding is divided into 19 anatomical sites, including varying locations within the peripheral and autonomic nervous system, connective and soft tissue lesions, and overlapping lesions within multiple anatomic locations (Tables S1--S3).

Survival rates were calculated for each of the 34 histologic types of soft tissue sarcoma. Descriptive statistics were generated for all measures, including means, ranges, and standard deviations for continuous measures and frequencies and proportions for categorical data. Overall survival (OS) was calculated from the date of diagnosis to the last known date of follow-up or the date of death. Sarcoma-specific death was not reported. Estimates of survival were calculated by using the Kaplan--Meier (product-limit) method and the log-rank test was used to assess statistical significance. Cox proportional hazards models were fit to assess survival differences adjusting for demographic and clinical covariates. Statistical significance was defined as *P* \< 0.05. All analyses were performed using SAS 9.3 (Cary, NC). We grouped certain similar histological subtypes together and combined other histologic sarcomas to create the ten graphs (Figs.[1](#fig01){ref-type="fig"} and [2](#fig02){ref-type="fig"} with text, Figs. [3](#fig03){ref-type="fig"}--[10](#fig10){ref-type="fig"} available as supplement) illustrating the Kaplan--Meier survivorship curves of the 34 sarcomas.
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![Malignant fibrous histiocytoma (MFH), giant cell, and poorly differentiated soft tissue sarcomas.](cam40003-1404-f3){#fig03}
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![Miscellaneous soft tissue sarcomas.](cam40003-1404-f8){#fig08}

![Osteosarcoma, NOS of soft tissue.](cam40003-1404-f9){#fig09}

![Ewings family of soft tissue sarcomas.](cam40003-1404-f10){#fig10}

Data reported to the NCDB are retrospective in nature. No patient or physician identifiers were collected as part of this study. Case identification information (facility identification number and local registry accession number) was collected for administrative purposes only. The ACOS has executed a Business Associate Agreement that includes a data-use agreement with each of its CoC-accredited hospitals. Results reported in our study were in compliance with the privacy requirements of the Health Insurance Portability and Accountability Act of 1996 as reported in the Standards for Privacy of Individually Identifiable Health Information, Final Rule (45 CFR Parts 160 and 164). Although this study is IRB-exempt, the IRB in place at each of the sites employing the authors reviewed the research proposal and confirmed IRB exemption status.

Results
=======

The demographic data for each sarcoma, the particulars of which is one of the primary questions sought by this study, are presented in Tables [1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"} and in Tables S1--S4. Gender, age, and race are displayed in Table [1](#tbl1){ref-type="table"}. The overall gender predilection demonstrated that soft tissue sarcomas are more common in males than in females, by a 1.23 to 1.00 ratio. Two soft tissue sarcomas demonstrated an overall female predilection. Malignant hemangiopericytoma and hemangiosarcoma displayed a sex predilection of 1.00:1.27 and 1.00:1.08 male: female ratio, respectively. Three sarcomas displayed nearly equal sex distribution: myxosarcoma, osteosarcoma NOS, and rhabdomyosarcoma NOS. Excluding the two female predominant tumors and the three gender equal tumors, the male/female ratio for the remaining 29 sarcomas was 1.26 to 1.00. The age distributions are displayed in Tables [1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}. (The NCDB *β*PUF program did not share data on patients under 18 years of age.) The tumor demonstrating the oldest median age of all ages in years at time of diagnosis is Angiomyosarcoma (69 median, 68.1 mean); followed by MFH (68 median, 65.9 mean) and Giant-Cell Sarcoma (65 median, 64.2 mean). The two youngest reported patient populations were Alveolar Rhabdomyosarcoma (25 median, 32.5 mean) and Alveolar Soft Part Sarcoma (27 median, 30.9 mean). Table [2](#tbl2){ref-type="table"} demonstrates that the most common decade of age for adult patients to be diagnosed with soft tissues sarcoma is during the eighth decade of life, followed by seventh and sixth decade of life.

###### 

Demographic and survivorship data for 34 soft tissue sarcomas

  Histology                                      N       Median   Male    Female   White   Black   Hispanic   Asian/PI   Other/Unknown   2-year survival (%)   5-year survival (%)
  ---------------------------------------------- ------- -------- ------- -------- ------- ------- ---------- ---------- --------------- --------------------- ---------------------
  Alveolar soft part sarcoma                     306     27.0     155     151      169     78      34         18         7               74                    47
  Angiomyosarcoma                                55      69.0     27      28       45      4       6          0          0               56                    39
  Chondrosarcoma, dedifferentiated               52      61.5     28      24       37      5       4          2          4               43                    19
  Chondrosarcoma, mesenchymal                    125     39.0     72      53       86      21      13         3          2               64                    46
  Chondrosarcoma, myxoid                         754     56.0     481     273      573     94      51         19         17              80                    68
  Chondrosarcoma, NOS                            527     58.0     327     200      425     34      30         17         21              78                    67
  Dermatofibrosarcoma, NOS                       2417    43.0     1216    1201     1425    670     162        78         82              97                    92
  Ewings (including PNET)                        1340    32.0     752     588      1040    72      147        55         26              61                    44
  Fibromyxosarcoma                               2835    60.0     1508    1327     2332    221     137        67         78              86                    73
  Fibrosarcoma, NOS                              1977    55.0     1024    953      1480    274     130        42         51              76                    60
  Fibrous histiocytoma, malignant                12754   68.0     7154    5600     10573   1072    618        286        205             69                    52
  Giant-cell sarcoma                             3415    65.0     1958    1457     2789    310     160        87         69              61                    42
  Hemangioendothelioma, epithelioid, malignant   191     48.0     88      103      150     18      13         5          5               70                    62
  Hemangioendothelioma, malignant                66      50.0     37      29       51      9       5          0          1               59                    49
  Hemangiopericytoma, malignant                  529     56.0     238     291      418     47      37         17         10              80                    67
  Hemangiosarcoma                                3372    69.0     1623    1749     2764    319     148        80         61              43                    26
  Liposarcoma, Dedifferentiated                  1509    66.0     971     538      1251    98      93         32         35              72                    53
  Liposarcoma, myxoid                            3996    49.0     2354    1642     2998    381     431        82         104             88                    77
  Liposarcoma, NOS                               2624    64.0     1466    1158     2050    259     197        68         50              83                    69
  Liposarcoma, Pleomorphic                       1551    65.0     902     649      1263    153     73         35         27              70                    50
  Liposarcoma, round cell                        410     49.0     245     165      315     42      31         14         8               78                    58
  Liposarcoma, well differentiated               3794    63.0     2207    1587     3032    318     240        107        97              92                    84
  Myxosarcoma                                    484     61.5     243     241      371     57      32         18         6               80                    65
  Osteosarcoma, NOS                              438     59.0     213     225      323     60      36         8          11              60                    41
  Rhabdomyosarcoma, alveolar                     348     25.0     192     156      229     64      37         13         5               43                    20
  Rhabdomyosarcoma, embryonal                    254     37.0     160     94       181     39      24         5          5               51                    38
  Rhabdomyosarcoma, NOS                          505     52.0     262     243      333     87      64         13         8               38                    24
  Rhabdomyosarcoma, Pleomorphic, adult type      526     63.0     344     182      414     57      32         12         11              43                    27
  Sarcoma, epithelioid                           1035    46.0     647     388      796     119     74         24         22              62                    49
  Sarcoma, NOS                                   7842    63.0     4232    3610     6079    919     479        213        152             47                    35
  Sarcoma, spindle-cell                          3927    63.0     2063    1864     3010    458     261        100        98              53                    39
  Synovial sarcoma, biphasic                     732     40.0     387     345      538     84      66         23         21              85                    65
  Synovial sarcoma, NOS                          1820    41.0     953     867      1316    212     197        49         46              71                    52
  Synovial sarcoma, spindle cell                 1204    41.0     616     588      850     120     171        28         35              77                    56
  Totals                                         63714            35145   28569    49706   6775    4233       1620       1380                                  

###### 

Age distribution of 34 soft tissue sarcomas

                                                 Age at diagnosis                                                
  ---------------------------------------------- ------------------ ------ ------ ------- ------- ------- ------ -------
  Alveolar soft part sarcoma                     184                67     28     16      5       6       0      306
  Angiomyosarcoma                                2                  3      2      6       15      7       20     55
  Chondrosarcoma, Dedifferentiated               0                  5      9      10      16      6       6      52
  Chondrosarcoma, mesenchymal                    34                 30     20     15      10      11      5      125
  Chondrosarcoma, myxoid                         32                 84     143    177     163     97      58     754
  Chondrosarcoma, NOS                            34                 66     75     105     96      111     40     527
  Dermatofibrosarcoma, NOS                       411                588    610    441     184     132     51     2417
  Ewings (including PNET)                        592                283    219    122     64      43      17     1340
  Fibromyxosarcoma                               182                262    407    534     545     491     414    2835
  Fibrosarcoma, NOS                              196                256    336    357     285     336     211    1977
  Fibrous histiocytoma, malignant                273                580    1258   2042    2531    3241    2829   12754
  Giant-cell sarcoma                             82                 158    349    661     769     769     627    3415
  Hemangioendothelioma, Epithelioid, malignant   20                 31     50     37      26      22      5      191
  Hemangioendothelioma, malignant                7                  12     13     11      8       8       7      66
  Hemangiopericytoma, malignant                  25                 69     96     127     100     79      33     529
  Hemangiosarcoma                                129                173    291    464     642     879     794    3372
  Liposarcoma, dedifferentiated                  14                 41     154    300     387     359     254    1509
  Liposarcoma, myxoid                            350                739    1007   779     522     390     209    3996
  Liposarcoma, NOS                               44                 152    350    543     570     602     363    2624
  Liposarcoma, pleomorphic                       26                 68     166    301     364     390     236    1551
  Liposarcoma, round cell                        27                 84     107    79      52      44      17     410
  Liposarcoma, well differentiated               49                 172    544    826     943     807     453    3794
  Myxosarcoma                                    14                 31     81     89      99      86      84     484
  Osteosarcoma, NOS                              35                 35     60     91      88      77      52     438
  Rhabdomyosarcoma, alveolar                     206                47     40     19      15      14      7      348
  Rhabdomyosarcoma, embryonal                    96                 42     39     28      27      11      11     254
  Rhabdomyosarcoma, NOS                          126                61     44     75      68      76      55     505
  Rhabdomyosarcoma, Pleomorphic, adult type      20                 34     64     93      129     105     81     526
  Sarcoma, epithelioid                           219                178    186    171     110     106     65     1035
  Sarcoma, NOS                                   483                590    982    1369    1404    1615    1399   7842
  Sarcoma, spindle cell                          237                325    487    684     728     810     656    3927
  Synovial sarcoma, biphasic                     202                152    165    106     71      27      9      732
  Synovial sarcoma, NOS                          489                382    400    251     153     87      58     1820
  Synovial sarcoma, spindle cell                 319                263    260    193     88      61      20     1204
  Total                                          5159               6063   9042   11122   11277   11905   9146   63714

The overall race distribution is displayed in Table [1](#tbl1){ref-type="table"} and include 78% white, 10% black, 6% Hispanic, 2.5% Asian/Pacific islander. EPub Tables S1--S3 display the primary anatomic sites. The most common anatomic site where these soft tissue sarcomas are diagnosed is in the connective and subcutaneous tissues of the lower limb and hip. The overall distribution of soft tissue sarcomas in this database by year of diagnosis is displayed in ePub Table S4. This shows that the overall numbers of soft tissue sarcomas reported to the NCDB increased over this time span. Overall, the most common defined sarcoma grade at the time diagnosis was coded as poorly differentiated (25%). The grade and size of each sarcoma at the time of diagnosis is displayed in Epub Table S5.

There has been some variation in the number of sarcomas reported to the NCDB over this 13-year period. In order to investigate this interval change, the percent increase or decrease in the reported sarcomas was calculated using an average of the first 3 years of this series (1998--2000) compared to the last 3 years of this series (2008--2010). The average number of cases reported in the first 3 years was 4491, compared to an average of 5362 reported in the last 3 years. By this analytic methodology, the overall number of reported soft tissue sarcoma increased by 19% over this 13-year interval.

The 2-year and 5-year survival for patients with each type tumor is displayed in Table [1](#tbl1){ref-type="table"}. The overall best prognosis is for patients diagnosed with dermatofibrosarcoma NOS (97% 2-year, 92% 5-year) and is followed by Well-differentiated liposarcoma (92%, 84%). The three sarcomas demonstrating the worst prognosis appear to be rhabdomyosarcoma, NOS (38%, 24%), dedifferentiated chondrosarcoma (43%, 19%), and pleomorphic rhabdomyosarcoma, adult type (43%, 27%).

Biphasic synovial sarcoma was determined to demonstrate a better 5-year survivorship (65%) than spindle-cell synovial sarcoma (56%, *P* \< 0.031) and Synovial Sarcoma, NOS (52%, *P* \< 0.001). A similar progressive decrease in survivorship was demonstrated within histologically-related subtypes of the Liposarcoma family. As more and less well-differentiated subtypes of Liposarcomas were compared, they presented a range of survivorships depending on the histology and its level of differentiation. The survivorships of the well-differentiated subtype, myxoid subtype, round cell subtype, and pleomorphic subtype were compared to liposarcoma NOS and ranged from 84% in the well-differentiated subtype (*P* \< 0.010) to 50% in the Pleomorphic subtypes (*P* \< 0.630 when compared to the 69% 5-year survivorship of liposarcoma, NOS). Additionally, the 5-year survivorship in the myxoid subtype was 77% (*P* \< 0.562) and 58% in round cell liposarcoma (*P* \<0.038 when compared to liposarcoma, NOS).

Discussion
==========

This report represents the single largest series of patients for each of the 34 soft tissue sarcomas. It also contains the most highly populated survivorship curves for patients with these 34 soft tissue sarcomas. While the database has limitations, the demographic and survival data are unprecedented in number and duration. (Our search strategy employed searching the textbook references cited earlier. In addition, the authors performed a PubMed search investigating the largest collections of each of the 34 soft tissue tumors. No larger series for each sarcoma were found.)

This series demonstrated demographic data (age/gender/race) in accordance with most previously published reviews of large case series for each of the entities [@b1]. It confirmed that soft tissue tumors are more common in males than in females (1.23 to 1.00). Excluding the five sarcomas that did not display male predominance, the sex predilection was 1.26 to 1.00. However, Malignant Hemangioendothelioma and Hemangiosarcoma were more common in females, displaying sex predilection of 1.00--1.27 and 1.00--1.08, respectively. The female sex predilection of malignant hemangioendothelioma and hemangiosarcoma is a new finding as previous series have found nearly equal gender distributions [@b7],[@b8]. The overall race distribution is displayed in Table [1](#tbl1){ref-type="table"} and includes 78% white, 10% black, 6% Hispanic, 2.5% Asian/Pacific islander, generally mirroring that of the population of the United States (78% white, 13% black, 17% Hispanic, 5% Asian/Pacific islander; <http://quickfacts.census.gov/qfd/states/00000.html>) [@b9].

The survivorship data includes more patients diagnosed with most of these soft tissue sarcomas than any prior case series. This enables us to present a more accurate representation of patient survivorship than noted in previously reported smaller series of patients, which are often derived primarily from single institution databases and are often limited to patients with sarcomas of certain stage, anatomic location, and/or treatment. The single largest report of which we are aware included 26,758 soft tissue sarcomas [@b2]. It included the demographic information containing 615 Synovial-Cell Sarcomas, 3085 Liposarcomas, and 4577 MFH. It also reported the anatomic location of each soft tissue sarcoma, as well as gender and race distribution. However, it did not report the survivorship of these soft tissue sarcomas. The largest series reporting survivorship data on Synovial-Cell Sarcoma contained 243 patients [@b10]. The current series contains 3755 patients diagnosed with Synovial-Cell Sarcoma. The largest series of Liposarcoma containing survivorship data that we could find contained 155 patients [@b11], while this series contains 12,367 patients diagnosed with Liposarcoma. The largest series of MFH containing survivorship data contained 338 patients [@b12], while this series contains 12,367 patients diagnosed with MFH.

Overall, most of our 5-year survivorships are within the range of previously published data. For example, the reported 5-year survival of synovial sarcomas can range from 36% to 76% [@b10],[@b13]--[@b17]. Our data demonstrated survivorships of 52%, 56%, and 65% for Synovial Sarcoma, NOS, Spindle Cell, and Biphasic, respectively. However, the reported survival rates tended towards the lower ranges of previously reported rates. Two tumors were found to demonstrate poorer survival than previously reported. The lowest previously reported 5-year survivorship for Dedifferentiated Chondrosarcoma was 24% [@b18], while these data revealed a 5-year survivorship of 19%. Similarly, the 5-year survivorship of Epithelioid Sarcoma has been reported to be only as low as 50% [@b19]--[@b22], while our data demonstrated a slightly lower 5-year survivorship of 49%.

One tumor was found to demonstrate a higher 5-year survivorship than previously reported. Alveolar Rhabdomyosarcoma survivorship has been quoted as low as 2% ranging to 10% [@b23],[@b24] while our data revealed a 5-year survivorship of 20%. This may reflect that most reported series are in the pediatric population, whereas this database is limited to patients 18 years of age or older.

As displayed in the ePub online version of this manuscript, Graphs 1--10 display statistically significant survivorship curves for many of the histologic subtypes within different families of soft tissue sarcomas. For example, Graph 2 displays that the survivorship of individuals diagnosed with Liposarcoma is dependent upon the histologic subtype of Liposarcoma. As displayed, the 5-year survivorship can range from 84% (*P* \< 0.010) in those patients diagnosed with well-differentiated Liposarcoma to 50% (*P* \< 0.630) in those patients diagnosed with pleomorphic Liposarcoma (*P* values derived from survivorship curve comparison to that observed with Liposarcoma, NOS). Similarly, Graph 1 demonstrates that the 5-year survivorship of synovial sarcoma can range from 65% (biphasic synovial sarcoma) to 52% (synovial sarcoma, NOS, *P* \< 0.001). These differences in survivorship within the same family of sarcomas provide prognostic information for future patient care**.**

The overall number of reported soft tissue sarcoma increased by 19% over this 13-year interval. This increase in the overall number of soft tissue sarcomas reported over the 13-year time interval may be due to a number of different reasons: including an increase in the actual number of soft tissue sarcomas, or it may be attributable to an increase in clinical awareness of these sarcomas, an increase in their reporting, an increase in the likelihood of catchment of potential tumors due to mergers of facilities, an increase in the quality of diagnostic procedures or other as yet unrecognized reasons. While the numbers of soft tissue sarcomas reported to the NCDB has increased by 19% over this 13-year time period, the number of bone sarcomas reported to the NCDB has increased by only 10.7% during this same time period (unpublished NCDB data- manuscript being prepared for publication consideration). The reason(s) for this difference is unknown.

This increase in the reported number of cases was not consistent across all histologies. There have been global changes in diagnostic tendency as evidenced by the 2002 World Health Organization declassification of MFH as a normal diagnostic entity which was renamed Undifferentiated Pleomorphic Sarcoma, NOS [@b25]. Some of the largest increases noted during this series are Fibromyxosarcoma (326% increase), Giant-Cell Sarcoma (540% increase), Liposarcoma, dedifferentiated (171% increase), and Synovial sarcoma, spindle cell (185% increase). Two notable decreases in the number of reported cases during this 13-year interval are Fibrosarcoma, NOS (29% decrease), and MFH (54% decrease). This decrease in MFH is the largest decease in numbers over this interval and is consistent with the evolution in diagnostic tendency alluded to above. Similarly, when these tumors cannot be subclassified, many pathologists have begun to diagnose these tumors more recently as Pleomorphic Sarcoma, NOS (Senior author, pers. obs.). Consistent with this theory, the number of reported cases of Sarcoma, NOS has increased by 27% over this same time interval.

A number of previous studies of these soft tissue sarcomas have lumped together many of the various histologic subtypes when calculating survivorship rates. By analyzing each histologically distinct tumor, more accurate survival data have been generated. Because of the large number of cases presented in this report, and the fact that each center reports each diagnosed case, it is less subject to bias that can be introduced by referral patterns to individual centers, a source of potential bias in previous reports. Furthermore, by not selecting out certain patients for inclusion or exclusion as has frequently been done in previously reported series, such as selecting only patients undergoing attempts at curative resection, these data are thought to be more reflective of the true overall prognosis for unselected patients following diagnosis.

There are a number of limitations to this data set. Some are inherent in any large registry such as the NCDB. These include the establishment of the histologic diagnoses by multiple pathologists in multiple institutions. Their interpretations of the histologic material of these uncommon sarcomas could vary and may introduce bias, especially considering that certain diagnostic terms may gain or lose favor over time, such as was mentioned in the prior discussion on MFH. There may be selection bias, based on the characteristics of contributing versus noncontributing sites, but since the NCDB captures an estimated 70% of all cancers treated, it is likely that any selection bias effect is minimal due to this high level of inclusion. Another major limitation is the methodology of the case entries by hospital-based coding personnel, who largely rely on medical records which may at times be incomplete, inaccurate or improperly reported. Although the data are highly specific and well defined by the FORDS manual, some items may not be as well documented as other items. These data have been collected over a long period of time. By necessity, the documentation for and the coding of the data have involved thousands of surgeons, hospital personnel, and coding staff at hundreds of institutions. Many of those involved at any given institution have likely changed over time, adding to the numbers and potential variations in data documentation and coding.

The treatment centers may not be aware of some patient\'s death, as deaths may occur at facilities far removed from the original reporting treatment centers. Precise cause of death information is not reported from hospital cancer registry sources, therefore limiting computation of adjusted survival rates. However, for the various hospitals to maintain their accreditation as an ACOS CoC-accredited hospital, there is significant leverage placed on the individual institutional registries to accurately report the data. Each accredited institution must follow 90% of living patients first seen at the facility for 5 years, and 80% for the lifetime of the facility\'s registry, thereby ensuring a high degree of follow-up reliability <http://www.facs.org/cancer/coc/programstandards2012.pdf>.

In addition, the reported survivorship between each histologic subtype was not stratified based upon risk factors or treatments.

As this *β*PUF program was limited to the reporting of patients greater than 18-years old, we did not have demographic data generated for those patients under the age of 18 who have been diagnosed with soft tissue sarcomas. This presumably affected the rhabdomyosarcoma demographic data in that rhabdomyosarcomas typically predominate in children. Inclusion of the pediatric tumor data in future NCDB analyses will provide accurate epidemiologic and survival data for pediatric patients diagnosed with soft tissue sarcomas.

In summary, the data reported herein contains demographic and survivorship data on 34 distinct soft tissue sarcomas in 63,714 patients. These data are unprecedented in its scope and size and provides an accurate oversight picture of the number of such cases in the USA and the true overall associated survivorship for these entities over the years reported. These data should form a reference baseline for comparisons of future series.

Conflict of Interest
====================

None declared.

Supporting Information
======================

Additional Supporting Information may be found in the online version of this article:

**Table S1.** Anatomic distribution of 34 soft tissue tumors -- Part 1.

**Table S2.** Anatomic distribution of 34 soft tissue tumors -- Part 2.

**Table S3.** Anatomic distribution of 34 soft tissue tumors -- Part 3.

**Table S4.** Year of diagnosis of 34 soft tissue tumors.

**Table S5.** Histologic grade and size of 34 soft tissue tumors.

[^1]: **Funding Information** No funding information provided.

[^2]: The data used in the study are derived from a de-identified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigator.

[^3]: Ethical Review Board: This confidential deidentified national registry data is exempt from review by individual Institutional Review Boards.

[^4]: Level of Evidence: Level 2 Registry data.
